XPO1 and cancer: In addition to the already available CRM1 and importin-α/ß inhibitors, agents that specifcally interfere with alternative nuclear import and export pathways would be extremely useful as tool compounds for cell biology research have the potential to become therapeutic anti-cancer drugs at a time that they are vitally required [140].